Halozyme Thrp Stock Price, News & Analysis

Halozyme Therapeutics (NASDAQ: HALO) announced that Janssen-Cilag received European Commission approval for DARZALEX Faspro®, co-formulated with Halozyme's ENHANZE® technology, for treating high-risk smouldering multiple myeloma (SMM) in adult patients.

This approval marks a significant shift from the current "Watch and Wait" standard of care, enabling early intervention in SMM patients before disease progression. The approval is based on the Phase 3 AQUILA study evaluating fixed-duration monotherapy daratumumab SC versus active monitoring in high-risk SMM patients.

Halozyme Therapeutics (NASDAQ: HALO) has scheduled the release of its second quarter 2025 financial and operating results for Tuesday, August 5, 2025, after market close. The company will host a conference call the same day at 1:30 p.m. PT/4:30 p.m. ET to discuss the results.

Investors can access the conference call through pre-registration and join the live webcast through Halozyme's investor relations website. A replay will also be available on the corporate website.

Halozyme Therapeutics (NASDAQ: HALO) has announced its addition to the U.S. large-cap Russell 1000® Index, effective after market close on June 27th, 2025, as part of FTSE Russell's annual index reconstitution. The Russell 1000® Index comprises approximately 1,000 of the largest U.S. securities based on market capitalization and serves as a key benchmark for large-cap stock performance.

According to CEO Dr. Helen Torley, this inclusion reflects the company's leadership in rapid large-volume subcutaneous drug delivery and their track record of durable top-and-bottom line growth. The membership in the Russell 1000® Index will remain in place for one year.

Halozyme Therapeutics announced that argenx received European Commission approval for VYVGART with ENHANZE for treating chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. The subcutaneous injection, available as a vial or prefilled syringe, is approved for patients previously treated with corticosteroids or immunoglobulins. VYVGART is notable as the first targeted IgG Fc-antibody fragment for CIDP and represents the first new treatment mechanism in over 30 years. The approval, based on the ADHERE clinical trial results, covers all 27 EU Member States plus Iceland, Norway, and Liechtenstein. This development marks a significant milestone in Halozyme's partnership with argenx and supports the company's growth strategy through expanded European market access.

Halozyme Therapeutics (NASDAQ: HALO) has announced its upcoming participation in two major investor conferences. The company's CEO, Dr. Helen Torley, will attend the Benchmark 2025 Healthcare House Call Virtual Conference on May 29, 2025, for one-on-one meetings. Additionally, she will participate in a fireside chat and investor meetings at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 9, 2025, at 7:00 AM PT / 10:00 AM ET.

The presentation at the Goldman Sachs conference will be available via live audio webcast in the Investor Relations section of Halozyme's website, with replays accessible for 90 days after the event.

Halozyme Therapeutics (NASDAQ: HALO) announced that Bristol Myers Squibb has received European Commission approval for a subcutaneous formulation of Opdivo® (nivolumab) developed with Halozyme's ENHANZE® technology. The approval covers multiple adult solid tumor indications and makes Opdivo® the first and only PD-1 inhibitor approved for subcutaneous use in the European Union.

The new formulation allows for a 3-to-5-minute subcutaneous injection, offering a more convenient alternative to traditional administration methods. The approval is supported by the Phase 3 CheckMate -67T trial and is valid across all 27 EU member states, plus Iceland, Liechtenstein and Norway. This follows the U.S. FDA approval of Opdivo Qvantig™ in December 2024.

Halozyme (NASDAQ: HALO) reported strong Q1 2025 results and raised its 2025 financial guidance. Total revenue increased 35% YOY to $265 million, with royalty revenue up 39% to $168 million. Net income grew 54% to $118 million, and GAAP diluted EPS rose 55% to $0.93. The company announced a new $250 million share repurchase program. Halozyme raised its 2025 guidance, projecting total revenue of $1,200-$1,280 million (18-26% YOY growth), royalty revenue of $750-785 million, and adjusted EBITDA of $790-840 million. Growth was driven by strong performance of blockbuster brands including Darzalex SC, Phesgo, and VYVGART Hytrulo, along with four recently launched products. The company also filed a patent infringement lawsuit against Merck regarding SC Keytruda development.

Halozyme Therapeutics (NASDAQ: HALO) announced that its President and CEO, Dr. Helen Torley, will present at the upcoming BofA Securities 2025 Healthcare Conference. The presentation is scheduled for Tuesday, May 13 at 4:20pm PT / 7:20pm ET. The company will provide a live audio webcast of the presentation on their Investor Relations website, with replays available for 90 days after the conference.

Halozyme Therapeutics (NASDAQ: HALO) has announced it will release its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, after market close. The company will host a conference call the same day at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. Investors can access the call through pre-registration and join the live webcast through the Investors section of Halozyme's corporate website.